The JAK inhibitor momelotinib provided a significant benefit in symptomatic patients with myelofibrosis and anemia, according to preliminary data from the phase 3 MOMENTUM study.
Of note, patients in this study were previously treated with a JAK inhibitor approved by the Food and Drug Administration (FDA). Preliminary results from this study demonstrate that momelotinib may be the first and only JAK inhibitor to demonstrate efficacy in improving symptoms, splenic size and anemia. Dr. Srdan Verstovsek, a researcher on the MOMENTUM study and professor of medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, explained that this development is important because these are the three issues patients with myelofibrosis often experience.
I'm really happy that we are in a situation where we are talking about potential for a new drug approval which covers the problems that we have not covered so far, he said in an interview with CURE.
Improving the Past
For the past 10 years, standard therapy has been Jakafi (ruxolitinib), with the option of Inrebic (fedratinib) added to standard care in the last two years. Both drugs have been shown to improve symptoms but worsen anemia, so they are limited in what they can do for a long period of time.
There are (several) different areas of interest; just looking at quality of life is No. 1, Verstovsek explained. What drives the therapy in myelofibrosis is improvement in quality of life. We want people to feel better, and we want them to feel better for a very long period of time. Along (with) that, we want them to improve the bone marrow function, lessen anemia, we want them to have a higher red blood cell count, eliminate the need for transfusions (and) that has been achieved here as well (with momelotinib) and then we want to decrease that spleen as well.
Verstovsek added, You have here a new medication that is able to tackle all three critical parameters that bother patients with myelofibrosis, the three parameters that we treat in a great majority of the patients. (Momelotinib is) certainly unique in its ability. (Jakafi) and (Inrebic) can control the spleen and symptoms but worsen the blood cell count, (but) not with momelotinib. (We) can improve quality of life, improve the anemia and improve the spleen all three at the same time.
In the MOMENTUM study, researchers assessed data from 130 patients with myelofibrosis who were unsuccessful with Jakafi and were treated with momelotinib, along with 65 patients treated with danazol after standard of care.
Extremely Significant Results
Results demonstrated a total symptom score of at least 50% or greater (with higher scores indicating greater symptom severity) in 25% of patients in the momelotinib group and 9% in the danazol group. The splenic response rate, which is the percentage of patients who obtained a reduction in spleen volume of at least 35%, was 23% and 3%, respectively. Verstovsek said that these results are significant, especially for this patient population.
The results are extremely significant, particularly, for example, in the setting where the study was done, the study was done after standard practice (Jakafi) failed, so resistant/refractory patients to (Jakafi), where patients are much more anemic than at the beginning of the therapy with (Jakafi), he explained. They may have lower platelets, they still have issues with the spleen, and they still certainly have a bad quality of life. What do you do? The life is bad, life is short also.
Verstovsek added, In that setting, you could use, for example, in some selected patients this other approved JAK inhibitor, (Inrebic), but it worsens the blood cell count, so it's not really applicable. And you say, what do I do? We can use prednisone, we can use danazol or an anabolic steroid to perhaps patch the problem a little bit, but it does not work. And momelotinib, particularly in this setting, is a discovery medication that has a potential to revise the outlook for the patients that have failed (Jakafi) by tackling all the critical three problems.
Additionally, momelotinib was able to control and improve anemia in patients, which Verstovsek highlighted as a differentiating factor from other drugs in the space.
Momelotinib has no medications to compare to. Because there are no other medications that tackle all the three problems at the same time. Certainly, we can say how about comparing the spleen control or the quality of life control with (Jakafi) or (Inrebic). But to say there is also a possibility of controlling the anemia (with momelotinib), then that's the differentiating factor. That's something that no other drug does. And that's why we are so excited about the prospect of having medication for our patients that will tackle those. So comparisons might be partial, but when you look at the total quality of what momelotinib does, it certainly stands on its own, he said.
Verstovsek added that because momelotinib improves anemia, it also makes some patients transfusion independent, leading to a longer life, which is my, as an academic physician, ultimate goal, he said.
Side Effects
Severe or worse side effects occurred in 54% of patients in the momelotinib group and 65% in the danazol group, which, Verstovsek explained, is a testament to the safety of momelotinib. Specific side effects are not known yet; however, in the past with momelotinib, there has been occasional dizziness, indigestion or a skin rash. Verstovsek noted that this was not a leading issue that his team was concerned about.
Overall, he said momelotinib is safe and simple, especially as patients only have to take one pill a day, which doesnt require much adjustment.
Nobody worries about too much side effects. And that can eventually, through control of these parameters, particularly anemia, then lead to durability and life extension at the end. We need to study that life extension much more in detail, but certainly I'm a believer in being able to make people live longer with good control of signs and symptoms, he said.
Next Steps
There are plans to submit an application this year to the FDA for potential approval of momelotinib in this setting. Verstovsek said that this is exciting and that may change the outlook for patients in this setting.
Certainly if the drug is approved, as I would expect it to be in the very near future, momelotinib will be, by far, the No. 1 choice for therapy in the setting where it was tested, he said.
There is also potential for momelotinib to be combined with other drugs, similarly to Jakafi, in the future to enhance its effectiveness. Verstovsek explained that since both drugs dont have any leading toxicities, they may be good combination partners.
I think it would be embraced by the very large group of patients right away where there was no option after (Jakafi) and in patients in frontline setting where you haven't even given any therapy, and they're already requiring transfusions or are significantly anemic and suffer from the spleen symptoms, Verstovsek concluded. It is qualitatively (a) different medication than anything so far. I think it will be a major, major drug for our patients with myelofibrosis.
For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.
See the article here:
Momelotinib 'Stands On Its Own' Compared With Other JAK Inhibitors for Myelofibrosis - Curetoday.com
- Choosing Regular Food to Extend Longevity - CounterPunch.org - CounterPunch - April 18th, 2024 [April 18th, 2024]
- "I love the club, I'm really happy here" - Manchester United star opens up on life at club amid contract extension uncertainty - Sportskeeda - March 31st, 2023 [March 31st, 2023]
- Life Extension review - 7 facts you should know [APRIL 2022] - February 5th, 2023 [February 5th, 2023]
- Biomedical Research & Longevity Society - Wikipedia - January 27th, 2023 [January 27th, 2023]
- NAD+ Cell Regenerator and Resveratrol Elite - Life Extension - December 26th, 2022 [December 26th, 2022]
- FLORASSIST GI with Phage Technology - Life Extension - December 12th, 2022 [December 12th, 2022]
- Magnesium Citrate 100 mg, 100 capsules - Life Extension - November 5th, 2022 [November 5th, 2022]
- AMPK Metabolic Activator, 30 tablets - Life Extension - November 5th, 2022 [November 5th, 2022]
- Germany nuclear plants life extension approved by Cabinet - DW (English) - October 19th, 2022 [October 19th, 2022]
- Biohacking: What is it, types and hacks to try for beginners - Medical News Today - October 19th, 2022 [October 19th, 2022]
- 'Biggest day of my life': Kevin Porter Jr., Rockets react to extension - Rockets Wire - October 19th, 2022 [October 19th, 2022]
- Postharvest quality solution for tomatoes-on-the-vine - hortidaily.com - October 19th, 2022 [October 19th, 2022]
- JZZ Technologies, Inc. and Subsidiary LION Development Group, Enter into JV Agreement with affiliate of Hospitality Development Group, Inc. of Florida... - October 19th, 2022 [October 19th, 2022]
- 'I love the city': QB Zach Collaros inks 3-year contract extension to stay with Blue Bombers through 2025 - CBC.ca - October 19th, 2022 [October 19th, 2022]
- MSU-led team studying expansion of controlled environment culinary herb production across US - Michigan State University - October 19th, 2022 [October 19th, 2022]
- 60 seconds with...Wayne Dunn, Babcock International - Professional Engineering - October 19th, 2022 [October 19th, 2022]
- Wind energy operators must address these 5 areas to exploit the full value of monitoring - Windpower Engineering - October 19th, 2022 [October 19th, 2022]
- Extension shares tips for practicing fire safety in the fall - The Hartselle Enquirer - Hartselle Enquirer - October 19th, 2022 [October 19th, 2022]
- FIRST Robotics Prepares to Extend Its Reach to More Vermont Students - Seven Days - October 19th, 2022 [October 19th, 2022]
- Plant Life Cycles - Penn State Extension - October 2nd, 2022 [October 2nd, 2022]
- FDA Authorizes Shelf Life Extension for Certain Lots of Paxlovid - October 2nd, 2022 [October 2nd, 2022]
- EDF considers extending life of two UK nuclear plants due to energy crisis - The Guardian - October 2nd, 2022 [October 2nd, 2022]
- Rittenbach among Extension team professionals honored - Jamestown Sun | News, weather, sports from Jamestown North Dakota - The Jamestown Sun - October 2nd, 2022 [October 2nd, 2022]
- What is the circular economy and why is it essential for real sustainability? - Schroders - October 2nd, 2022 [October 2nd, 2022]
- 44 national and international NGOs call for renewal and expansion of truce in Yemen [EN/AR] - Yemen - ReliefWeb - October 2nd, 2022 [October 2nd, 2022]
- University City Townhomes residents now have until end of the year to find new low-income housing - The Philadelphia Inquirer - October 2nd, 2022 [October 2nd, 2022]
- New Eskom board: Business groups happy with mix of skills - News24 - October 2nd, 2022 [October 2nd, 2022]
- Full circle on the farm: Penn State alum returns to help educate Pa. growers - Pennsylvania State University - October 2nd, 2022 [October 2nd, 2022]
- Task Force: Blacks are owed hundreds of thousands - CalMatters - October 2nd, 2022 [October 2nd, 2022]
- ProLynx appoints Richard King as Chief Executive Officer and Chris Ehrlich as Board Director - GlobeNewswire - September 20th, 2022 [September 20th, 2022]
- Analysis: Behind Trump's media deal, a vote where only yes will do - Reuters - September 20th, 2022 [September 20th, 2022]
- Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19 | Antibodies | News Channels - PipelineReview.com - September 20th, 2022 [September 20th, 2022]
- Action Hampshire get behind Sustainable Future Fund to reduce waste in business - Hampshire Chronicle - September 20th, 2022 [September 20th, 2022]
- Living the dream - Farm Progress - September 20th, 2022 [September 20th, 2022]
- Teck and Agnico Eagle Announce Agreement on the San Nicols Copper-Zinc Project located in Zacatecas, Mexico - PR Newswire - September 20th, 2022 [September 20th, 2022]
- Most actively traded companies on the Toronto Stock Exchange - Winnipeg Free Press - September 20th, 2022 [September 20th, 2022]
- Giants Urged to Give Extension to 24-Year-Old Defender - Heavy.com - September 20th, 2022 [September 20th, 2022]
- Russias MiG-31 Fighter That Fired Hypersonic Missiles On Ukraine Conducted Drills In The Stratosphere - EurAsian Times - September 20th, 2022 [September 20th, 2022]
- Jaguar Mining Reports Confirmed Continuity of Mineralization at Pilar Gold Mine - Life of Mine Extension Drilling to Follow - Yahoo Finance - September 14th, 2022 [September 14th, 2022]
- Easy meals, life-saving knife skills part of West Texas Fair & Rodeo Spotlight Kitchen - Abilene Reporter-News - September 14th, 2022 [September 14th, 2022]
- Beyond Bulletproof: Why Billionaires Are Chasing Everlasting Health - Newsweek - September 14th, 2022 [September 14th, 2022]
- Did California Truly Extend the Life of Diablo Canyon? Only Time Will Tell. - JD Supra - September 14th, 2022 [September 14th, 2022]
- Youth Mental Health First Aid Trainings Offered This Fall - Iowa State University - September 14th, 2022 [September 14th, 2022]
- Finland to Extend Validity of Residence Permits for Ukrainian Refugees Under Temporary Protection - SchengenVisaInfo.com - SchengenVisaInfo.com - September 14th, 2022 [September 14th, 2022]
- Wildfire Smoke's Affect on Potato Crops Being Studied - University of Idaho - September 14th, 2022 [September 14th, 2022]
- National Weather Service Northern Indiana radar will be down beginning Monday for upgrades - WANE - September 7th, 2022 [September 7th, 2022]
- Renault Trucks Will Give New Life to Old Parts - Ward's Auto - September 7th, 2022 [September 7th, 2022]
- Stop the stigma and step in - Farm Progress - September 7th, 2022 [September 7th, 2022]
- Empire Wind and WCS Announce Extension of Historic Near Real-Time Acoustic Marine Monitoring Project In New York Bight - Business Wire - September 7th, 2022 [September 7th, 2022]
- Media Advisory: Chalk River Laboratories Officially Breaks Ground on One of the Largest Nuclear Research Facilities Ever Constructed in Canada -... - September 7th, 2022 [September 7th, 2022]
- PFAS pilot study gets yet another extension, scope and cost of another project reduced - wausaupilotandreview.com - September 7th, 2022 [September 7th, 2022]
- Predators extend deal with Bally Sports South - Awful Announcing - September 7th, 2022 [September 7th, 2022]
- WWYDW: Reactions to the Canucks' J.T. Miller extension - Canucks Army - September 7th, 2022 [September 7th, 2022]
- NASA's Artemis rocket makers explain that it's a marathon and a sprint - The Register - September 7th, 2022 [September 7th, 2022]
- Food supply chains are susceptible to fraud and adulteration more than ever, warns Kerry - Food Ingredients First - September 7th, 2022 [September 7th, 2022]
- Reprieve for The White Lady as iconic food truck gets 12-month licence extension - Stuff - September 7th, 2022 [September 7th, 2022]
- Gypsy Moth Biology & Life Cycle - University of Illinois Extension - August 30th, 2022 [August 30th, 2022]
- AgriLife's Johanna Hicks and Team Honored at 2022 National Health Outreach Conference - frontporchnewstexas.com - August 30th, 2022 [August 30th, 2022]
- Harmony Gold to maintain dividends despite facing two years of heavy capital bills - Miningmx - August 30th, 2022 [August 30th, 2022]
- Malaysian, Thai companies ink MOU to explore cooperation in Mechanised Infantry Fighting Vehicle life extension programme - The Edge Markets MY - August 30th, 2022 [August 30th, 2022]
- Coveris previews new packaging solutions targeting enhanced performance and recyclability - Packaging Europe - August 30th, 2022 [August 30th, 2022]
- KPF and heatherwick studio to extend singapore airport as cluster of lush 'neighborhoods' - Designboom - August 30th, 2022 [August 30th, 2022]
- Understanding Tax Liens. Could the IRS seize your car? - finehomesandliving.com - August 30th, 2022 [August 30th, 2022]
- Extension of Legacy Trail in Tyler to continue - Tyler Morning Telegraph - August 29th, 2022 [August 29th, 2022]
- KRUG: Extension learning opportunities around the corner - Hays Post - August 29th, 2022 [August 29th, 2022]
- Half-Life 2 VR is coming, here's how you can get it - Win.gg - August 29th, 2022 [August 29th, 2022]
- Transplant technology: United Therapeutics 3D-printing of human organs focused on every breath you take - Manchester Ink Link - August 29th, 2022 [August 29th, 2022]
- Serena Williams Interview on Leaving Tennis and Her Legacy - TIME - August 29th, 2022 [August 29th, 2022]
- Thousands of photos captured by everyday Australians reveal the secrets of our marine life as oceans warm - The Conversation - August 29th, 2022 [August 29th, 2022]
- Empathy and Solidarity: On Alejandro Varela's The Town of Babylon - lareviewofbooks - August 29th, 2022 [August 29th, 2022]
- How many people continue their stay in the UK or apply to stay permanently? - GOV.UK - August 29th, 2022 [August 29th, 2022]
- Anti-Aging Conference and Olympia Weekend Set for Back-to-Back Weekends in Vegas - Muscle & Fitness - August 15th, 2022 [August 15th, 2022]
- A son steps aboard the Eagle and into his father's world - Journal Inquirer - August 15th, 2022 [August 15th, 2022]
- Class to teach healthy living for those with chronic conditions - The Maryville Forum - August 15th, 2022 [August 15th, 2022]
- New application for disinfection of fresh-cut fruits by means ozone in the packaging - hortidaily.com - August 15th, 2022 [August 15th, 2022]
- Meatless Meats and Smokeless Smokes - Equities News - August 15th, 2022 [August 15th, 2022]
- Command & Control Success: Fireground Commander: Understanding the Impact - Firehouse - August 15th, 2022 [August 15th, 2022]
- Five Ways This Survey About Maine's Wellness is Absolutely Bogus - WJBQ - July 25th, 2022 [July 25th, 2022]
- Center for Advanced Innovation in Agriculture, Virginia Cooperative Extension help Virginia Tech showcase its land-grant mission at 2022 Virginia Ag... - July 25th, 2022 [July 25th, 2022]
- Anti-ageing tips: Here's how to rewind your biological clock - Hindustan Times - July 25th, 2022 [July 25th, 2022]